IntroductionWhat We Can OfferWorkflowWhy Creative BiolabsCustomer ReviewsFAQsRelated ServicesContact Us
Creative Biolabs' service is designed to provide comprehensive, data-driven solutions for your immuno-oncology research. Creative Biolabs offers a suite of validated biochemical and cellular assays to accurately measure CD73 enzymatic activity and its downstream effects. Clients can expect specific deliverables and solutions tailored to their project's needs, whether it's identifying novel inhibitors, characterizing lead compounds, or understanding the role of CD73 in a specific cancer model. Our service is grounded in scientific rigor, providing you with the precise data you need to make informed decisions and advance your pipeline with confidence.
CD73 in Antitumor Immunity
CD73 expression on tumor microenvironment cells is regulated by HIF-1α. Upregulated CD39 and CD73 convert ATP to immunosuppressive adenosine, which binds to adenosine receptors on neoplastic cells, promoting cancer growth. CD39/CD73 also acts as 'immunological switches' that shift the immune response from pro-inflammatory to anti-inflammatory. This immunosuppressive environment affects immune cells like macrophages, dendritic cells (DCs), and T cells. For example, adenosine stimulates M2 macrophage polarization, suppresses DCs, and diminishes the function of antitumor T cells, while enhancing immunosuppressive regulatory T cells (Tregs).
Migration and invasion assay: wound healing assay, transwell assay
Cell apoptosis assay and Cytotoxicity assay
Immunofluorescence and Immunohistochemistry
In Vivo Tumorigenicity Assay
ELISA
Enzymatic Assays
Western Blot & Co-Immunoprecipitation
Workflow of CD73 Assay Portfolio Service
Highlights
Unmatched Scientific Expertise
Our team of experienced scientists specializes in the biology of CD73 and the purinergic pathway, possessing deep insight into its functions in immune suppression and cancer progression. This expertise allows us to design and interpret the most effective assays.
A Proven Track Record of Success
Our proven track record, demonstrated by compelling case studies, shows we help clients accelerate timelines and reduce costs. We generate the robust data needed to confidently advance your therapeutic candidates, de-risking your projects.
Comprehensive & Customizable Assay Portfolio
Our portfolio goes far beyond basic screening. We offer a full suite of biochemical, cellular, and in vivo assays. We provide tailored solutions to meet your needs at every stage of drug discovery, from initial hit identification to advanced mechanistic studies.
Reliability & Reproducibility
We ensure our meticulously validated and optimized assays provide high sensitivity and reproducibility. This commitment to quality control gives you accurate, trustworthy data, reducing the risk of false positives and allowing you to confidently advance your lead candidates.
Experience the Creative Biolabs advantage - Get a quote today.
Customer Reviews
Confidence in Our Data
Using Creative Biolabs' service has profoundly improved the reliability and reproducibility of our screening data. Our internal research faced challenges with assay variability, but their protocols allowed us to generate consistently robust results. - Cy R***n.
Accelerated Drug Discovery
Creative Biolabs' service facilitated the identification of a potent CD73 inhibitor far more rapidly. By leveraging their HTS platforms and expert-led project design, we were able to move from hit identification to lead optimization ahead of our projected schedule. - Pl Wn.
FAQs
How can your CD73 assays help me overcome drug resistance in my cancer model?
Our assays are meticulously designed to precisely measure CD73 activity in various cellular contexts, including cancer cell lines known for chemoresistance. We recognize that CD73-mediated adenosine signaling can promote an immunosuppressive environment that not only protects tumor cells from immune attack but also contributes to therapeutic resistance.
What advantages do your cell-based assays offer compared to standard biochemical screening?
While biochemical assays are excellent for initial high-throughput screening to identify raw binding or inhibition, our cell-based assays provide a more physiologically relevant context. They bridge the gap between simple test tube reactions and the complexity of a living system. Our cell-based assays allow you to assess critical factors such as a compound's cell permeability, off-target effects, and efficacy on CD73 expressed on a living cell's membrane.
Related Services
Antibody Drug Conjugate (ADC) Development
Our service includes selecting the optimal antibody for CD73 binding, choosing a suitable linker, and conjugating a potent cytotoxic payload, thereby creating a highly effective and targeted therapeutic agent.
Creative Biolabs' CD73 assay portfolio service provides the critical tools and expertise needed to confidently navigate the complex and promising field of immuno-oncology. From foundational biochemical screens to advanced cell-based functional assays, we offer a complete solution to accelerate your drug discovery program and help you find the next breakthrough therapeutic.
Contact us for more information and to discuss your project.
